Figure 7.

lnc-POP1-1 affected the cisplatin resistance of HNSCC cells by interacting with MCM5

(A) Compared with NC-transfected cells (black line), HN30 cells with MCM5 upregulation exhibited resistance to cisplatin (red line). The IC₅₀ values are shown on the right. (B) Compared with NC-transfected cells (black line), HN30/DDP cells with MCM5 downregulation were sensitized to cisplatin (blue line). The IC₅₀ values are shown on the right. (C) Cell viability was detected by CCK-8 assay when lnc-POP1-1 was knocked down in HN30 cells stably transfected with LV-MCM5. The IC₅₀ values are shown on the right. (D) Cell viability was detected by CCK-8 assay when lnc-POP1-1 and MCM5 were both knocked down in HN30/DDP cells. The IC₅₀ values are shown on the right. (E) Under intraperitoneal injection with 5 mg/kg cisplatin every 3 days 5 times, the tumor volumes and weights of the mice subcutaneously inoculated with LV-MCM5 HN30 cells treated with ASO-lnc-POP1-1/ASO-NC are shown (n = 6/group). (F) The tumor volumes of the four groups were calculated every 5 days. Cisplatin was injected intraperitoneally every 3 days 5 times. (G) Under intraperitoneal injection with 5 mg/kg cisplatin every 3 days 5 times, the tumor volumes and weights of the mice subcutaneously inoculated with HN30/DDP cells and then treated with ASO-lnc-POP1-1 and/or si-MCM5 are shown (n = 6/group). (H) The tumor volumes of the four groups were calculated every 5 days. Cisplatin was injected intraperitoneally every 3 days 5 times. ∗p < 0.05, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001. Error bars, means ± SDs.